Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orion-BC: ONCOFID-P-B in BCG-unresponsive Bladder Carcinoma in Situ
NCT05024773Phase 3Active, not recruiting
- Sponsor
- Fidia Farmaceutici
- Start
- Dec 2022
- Primary completion
- May 2028
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of Oncofid-P-B in bladder carcinoma in situ (CIS), sponsored by Fidia Farmaceutici. Started Dec 2022; status: active, not recruiting.
02
Drugs
Oncofid-P-B
03
Conditions
bladder carcinoma in situ (CIS)
Beyond the preview
Go deeper on NCT05024773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024773.